Theriva Biologics (TOVX) said AEMPS has authorized initiation of the Phase 2a VIRAGE2 clinical trial for VCN-0. This regulatory greenlight advances the company’s oncology pipeline into a later-stage study, which is a modest positive catalyst for near-term sentiment despite limited financial impact information in the release.
Theriva Biologics (TOVX) said AEMPS has authorized initiation of the Phase 2a VIRAGE2 clinical trial for VCN-0. This regulatory greenlight advances the company’s oncology pipeline into a later-stage study, which is a modest positive catalyst for near-term sentiment despite limited financial impact information in the release.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
